Erratum to: Phase 1 study of darolutamide (ODM-201), a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer

Cancer Chemother Pharmacol. 2017 Dec;80(6):1073-1077. doi: 10.1007/s00280-017-3433-3.

¹ Division of Breast and Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, Japan. nmatsuba@east.ncc.go.jp.
² Division of Breast and Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, Japan.
³ Clinical Development, Bayer Yakuhin, Osaka, Japan.
⁴ Clinical Sciences Japan, Bayer Yakuhin, Osaka, Japan.
⁵ Clinical Statistics, Bayer Yakuhin, Osaka, Japan.
⁶ Clinical Pharmacology Oncology, Bayer AG, Berlin, Germany.

No abstract available

Publication types